Osimertinib improves progression-free survival in EGFR-mutated non-small-cell lung cancer: The FLAURA trial

Originally Published By 2 Minute Medicine®. Reused on ONA with permission.
Share this content:

1. Osimertinib demonstrated a significantly longer duration of progression-free survival compared to standard of care epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) in patients with untreated EGFR-mutated locally-advanced or metastatic non-small-cell lung cancer (NSCLC).

2. Osimertinib treated patients had fewer grade 3 or higher adverse events compared to patients treated with standard EGFR-TKI therapy.

Evidence Rating Level: 1 (Excellent)   

Study Rundown: Osimertinib is an oral third-generation, irreversible EGFR-TKI that inhibits both EGFR-sensitizing and EGFR T790M resistance mutations presently approved for previously treated patients with T790M-positive NSCLC. Although recent phase 1 data suggests osimertinib may be effective as first-line therapy for locally-advanced or metastatic EGFR-mutated NSCLC, it is not yet approved for this purpose. This study evaluated osimertinib versus standard of care EGFR-TKI therapy (gefitinib or erlotinib) in treatment naïve patients with locally-advanced or metastatic EGFR-mutated NSCLC. The duration of progression-free survival (primary end point) was significantly longer in the osimertinib group compared to standard therapy. Among secondary end points, osimertinib was associated with improved disease-control rate, reduction in tumor size, and fewer adverse events. The significant increase in progression-free survival supports use of osimertinib as the new standard of care for EGFR-mutated NSCLC.

Major strengths of this trial are the confirmation of EGFR-mutation type in the majority of patients, inclusion of patients with and without CNS metastases, and the comparison to the two most widely used EGFR-TKIs. As data for overall survival is still pending, however, universal use of osimertinib as first-line therapy may not be universally implemented. Additionally, magnetic resonance imaging was not required to detect brain metastasis, and asymptomatic metastases are well-documented in NSCLC.

Click to read the study, published today in NEJM

Relevant Reading: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

In-Depth [randomized controlled trial]: This was a double-blind, phase 3 trial of patients with locally-advanced or metastatic NSCLC with a confirmed EGFR exon 19 deletion and/or p.Leu858Arg mutation. Patients (n = 556) were randomized in a 1:1 ratio to either oral osimertinib (n = 279) or a standard oral EGFR-TKI (gefitinib or erlotinib; n = 277) and assessed via the Response Evaluation Criteria in Solid Tumors (RECIST) criteria until disease progression. The primary end point was the duration of progression-free survival according to RECIST. Secondary end points included overall survival, objective response rate, duration of response, disease-control rate, and safety.

The median progression-free survival was 18.9 months (95% confidence interval [CI], 15.2 to 21.4) in the osimertinib group versus 10.2 months (95% CI, 9.6 to 11.1) in the standard EGFR-TKI group (hazard ratio [HR], 0.46; 95% CI, 0.37 to 0.57; p < 0.001). This increased duration was consistent across all predefined subgroups (including Asian versus non-Asian, EGFR mutation type, and presence or absence of central nervous system [CNS] metastases at trial entry). A statistically significant benefit was found in the osimertinib group with respect to disease-control rate (97% vs. 92%; odds ratio, 2.78; 95% CI, 1.25 to 6.78; p = 0.01) and median best percentage change in target-lesion size (-54.7% vs. -48.5% in standard group; p = 0.003). Events of CNS progression occurred in 6% in the osimertinib group versus 15% in the standard therapy group. No significant difference in objective response rate (odds ratio [OR], 1.27; 95% CI, 0.85 to 1.90; p = 0.24) was found. Median overall survival could not be calculated due to data immaturity. Adverse events of grade 3 or higher were reported in fewer patients in the osimertinib group (34% vs. 45%) and osimertinib was associated with a lower rate of adverse events leading to treatment discontinuation. QT interval prolongation was reported in a higher percentage of patients in the osimertinib group (10% vs. 5%); however, the majority were grade 1 or grade 2 and no fatal cases of torsades des pointes were reported in either group.

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Share this content:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs